Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson’s Janssen Biotech unit has licensed the immuno-oncology agent ADC-1013 from Sweden’s Alligator Bioscience. Currently in Phase I clinical trials, ADC-1013 is a monoclonal antibody that targets the receptor CD40 and initiates a process leading to an increase in T cells attacking a tumor. Separately, Janssen has licensed its Centyrin technology to San Diego’s Poseida Therapeutics. Centyrins are molecules that bind to proteins in a way similar to antibodies. Poseida says the technology can be used in immuno-oncology regimens to bind to cancer antigens.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X